CAFs are increasingly seen as an immunologic barrier against CD8+ T-cell-mediated antitumour effects, supported by a negative correlation of CD8+ T-cell infiltration and CAF density in tumours [46–48]. The gene discussed is CD8A; the disease is neoplasm.